Privately-held biopharmaceutical company Oncobiologics and inVentiv Health have partnered around clinical development for all assets in Oncobiologic's pipeline. The global partnership will initially focus on biosimilar assets, and could be expanded to include innovative molecules.

inVentiv Health will provide leadership and execution for clinical studies, as well as the corresponding bioanalytical support for those trials. As the assets are commercialized, the partnership will broaden to include inVentiv's commercialization capabilities in select countries.

The current biosimilar assets include generic versions of Humira, Rituxan, Avastin, Herceptin and Erbitux. These biologics have respective cancer and immune-disease indications, representing annual global revenue of more than $40 billion.

"This partnership spans both clinical and bioanalytical development as well as commercialization of our biosimilar assets. inVentiv is able to take the scope of these agreements to a much broader level by working across the full development life cycle of each biosimilar and innovator product while preparing for a successful market launch. With their willingness to share in the risk/reward of our development programs, our firms are a perfect fit, both technically and culturally," said Pankaj Mohan, Ph.D., Oncobiologics founder and chief executive officer.